Fig. 3.

Response rates for individual Itch numerical rating scale (NRS) scores for (A) ixekizumab-treated and (B) ustekinumab-treated patients through to week 52. Coloured areas: itch NRS responses. Solid vertical line: end of induction period (primary endpoint). Dotted vertical lines: active injections administered during the maintenance period. All patient visits during the maintenance period are represented on the x-axis. Due to missing data at some time-points, total response rates do not always add up to 100, as indicated by the white space at the top of each area plot.